Key Takeaways for Advancing Care in HR Positive Breast Cancer

In this closing segment, the panel offers practical pearls for clinicians navigating the rapidly evolving management landscape of HR positive breast cancer. Experts emphasize the importance of staying current with emerging data as CDK4/6 inhibitors, oral SERDs, and targeted combinations reshape standards across early stage and metastatic disease. They highlight the need for comprehensive education not only for oncologists but also for advanced practice providers and nursing teams to ensure confident toxicity monitoring, timely dose adjustments, and effective patient counseling. The panel underscores prioritizing quality of life, encouraging patients to report symptoms early, and tailoring therapy intensity to individual risk and preferences. Molecular profiling and biomarker driven decisions are identified as essential for personalizing care. Ultimately the panel reinforces that multidisciplinary collaboration, ongoing clinician education, and thoughtful shared decision making remain central to optimizing long term outcomes for patients living with HR positive breast cancer.